Currently Viewing:
COA 2017-ONCOLOGY PAYMENT REFORM
Currently Reading
Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk
February 12, 2018
Dr Peter Aran Discusses Year 1 Feedback on OCM
February 05, 2018
Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development
January 31, 2018
Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology
January 29, 2018
Bo Gamble Explains How COA Helps Practices Prepare for OCM
January 27, 2018
Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models
January 24, 2018
Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges
January 20, 2018
Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM
January 19, 2018
Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care
January 18, 2018
David Merrill and John Robinson Discuss Barriers to APMs, Factors of Interest
January 15, 2018
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12, 2018
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11, 2018
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10, 2018
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 09, 2018
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 07, 2018
Bo Gamble on COA's Role in 2018
January 05, 2018
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 04, 2018
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 03, 2018
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26, 2017

Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk

We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.


We want to know all sides of the 2-risk model, like with any challenge or strategy, said Roger Brito, DO, national director for oncology, Aetna.

Transcipt (slightly modified)

What are your thoughts on providers taking on 2-sided risk?

The 2-sided risk model, I think like any challenge or any strategy, is we want to know all sides. So, what’s the upside, what’s truly the downside, where’s our floor, and how high can our ceiling go? I think we’ll know that as OCM starts to look at reconciliation and looking at numbers and data distributions. I think we’ll find that some of the oncology care models then will put their toes in the water and try to see what a risk model would look like. I think as long as these risk models are outcome based and the goal is to improve quality, I don’t think that anyone would ever want an oncology practice to not do well and go bankrupt because of a payment model that’s developed. Obviously if that happens, we’ve done something wrong and we need to fix it.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!